Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial
Robert L. Grubb, Gerald L. Andriole(Institut thématique Génétique, génomique et bioinformatique), Robert T. Greenlee(Marshfield Clinic), E. David Crawford(University of California San Diego), David L. Levin(University of California San Diego), Philip C. Prorok(National Cancer Institute), John K. Gohagan(National Institutes of Health), Timothy R. Church(University of Minnesota), David Chia(University of California, Los Angeles), Edward P. Gelmann(University of Arizona), Paul F. Pinsky(National Cancer Institute), Anthony B. Miller(University of Toronto), Joel L. Weissfeld(University of Pittsburgh), Saundra S. Buys(University of Utah), Lance Yokochi(National Institutes of Health), Donald A. Urban(University of Alabama at Birmingham), Jerome Mabie(Information Management Services), Lawrence R. Ragard(Westat (United States)), Christine D. Berg(Prevention Group), Thomas Hickey(Information Management Services), Douglas J. Reding(Ascension), Barnett S. Kramer(University of Pittsburgh), Paul A. Kvale(Henry Ford Health System), Thomas L. Riley(Automation, Information, and Management Systems (United States)), Grant Izmirlian(National Institutes of Health)
Cited by 156
Related Papers
Reducing Mortality from Colorectal Cancer by Screening for Fecal Occult Blood
|New England Journal of Medicine|1993|3.3k
Mortality Results from a Randomized Prostate-Cancer Screening Trial
|New England Journal of Medicine|2009|2.9k
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
|JNCI Journal of the National Cancer Institute|2008|1.7k
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer
|Nature Genetics|2007|1.5k
Probability of Cancer in Pulmonary Nodules Detected on First Screening CT
|New England Journal of Medicine|2013|1.4k